Search IBA Dosimetry

SBRT part 1: Impact of PSMA PET on the management of patients with oligo metastatic prostate cancer

Jeremie Calais MD MSc

Director of the Clinical Research Program of the Nuclear Medicine and

Theranostics Division, UCLA

3 min. (open access preview)20 min. (full presentation, members)

Learn about the concept of oligometastatic disease on prostate cancer patients and the importance of highly sensitive and specific PET PSMA imaging in the therapy management of those patients.

Related Presentations

SBRT part 2: The role of SBRT in the treatment of oligometastatic prostate cancer: Why & how SBRT for these patients
Discover
SBRT part 3: Quality assurance for SBRT treatments
Discover